IDEXX Laboratories, Inc. logo

IDEXX Laboratories, Inc. (IDXX)

Market Closed
2 Mar, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
636. 70
-20.03
-3.05%
$
51.84B Market Cap
55.21 P/E Ratio
- Div Yield
521,423 Volume
9.84 Eps
$ 656.73
Previous Close
Day Range
627.38 647.04
Year Range
356.14 769.98
Want to track IDXX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
IDXX earnings report is expected in 57 days (29 Apr 2026)
Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?

Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?

Here is how Idexx Laboratories (IDXX) and Artivion (AORT) have performed compared to their sector so far this year.

Zacks | 2 months ago
3 Medical Instrument Stocks to Counter Industry Woes Using GenAI

3 Medical Instrument Stocks to Counter Industry Woes Using GenAI

VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.

Zacks | 2 months ago
IDEXX Laboratories Stock Rallies 75.6% YTD: What's Behind the Surge?

IDEXX Laboratories Stock Rallies 75.6% YTD: What's Behind the Surge?

IDXX surges 75.6% YTD as strong CAG Diagnostics momentum and high-demand software solutions fuel growth.

Zacks | 2 months ago
Idexx (IDXX) Up 1.5% Since Last Earnings Report: Can It Continue?

Idexx (IDXX) Up 1.5% Since Last Earnings Report: Can It Continue?

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?

Zacks | 2 months ago
Idexx (IDXX) Upgraded to Buy: Here's What You Should Know

Idexx (IDXX) Upgraded to Buy: Here's What You Should Know

Idexx (IDXX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 3 months ago
What Makes Idexx Laboratories (IDXX) a Strong Momentum Stock: Buy Now?

What Makes Idexx Laboratories (IDXX) a Strong Momentum Stock: Buy Now?

Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 3 months ago
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)

3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)

Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks | 3 months ago
Idexx Laboratories (IDXX) Recently Broke Out Above the 20-Day Moving Average

Idexx Laboratories (IDXX) Recently Broke Out Above the 20-Day Moving Average

From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

Zacks | 3 months ago
Pet Healthcare Spending Is Soaring. These Stocks Are Positioned to Clean Up

Pet Healthcare Spending Is Soaring. These Stocks Are Positioned to Clean Up

The steep increase in pet healthcare costs have doubled over the past five years, according to NPR.

247wallst | 3 months ago
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)

3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)

Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.

Zacks | 3 months ago
Idexx Laboratories (IDXX) Just Flashed Golden Cross Signal: Do You Buy?

Idexx Laboratories (IDXX) Just Flashed Golden Cross Signal: Do You Buy?

Idexx Laboratories (IDXX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IDXX broke through the 20-day moving average, which suggests a short-term bullish trend.

Zacks | 3 months ago
Idexx Laboratories (IDXX) Just Overtook the 50-Day Moving Average

Idexx Laboratories (IDXX) Just Overtook the 50-Day Moving Average

From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.

Zacks | 3 months ago
Loading...
Load More